Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
91-105 of 137
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
MinuteCE®Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
MinuteCE®Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Lauren A. Byers, MD
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Luis Paz-Ares, MD, PhD
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
MinuteCE®Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
- advertisement
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
MinuteCE®Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
MinuteCE®Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
- advertisement
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Jenny Seligmann, MBChB, PhD
Fortunato Ciardiello, MD, PhD
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD
Sandy Srinivas, MD
